Antipsychotic Polypharmacy. A Comprehensive Evaluation of Relevant Correlates of a Long-Standing Clinical Practice.

Psychiatric Clinics of North America

Volumn 35, Issue 3, 2012, Pages 661-681

  Correll, Christoph U ^a,b,c,d   Gallego, Juan A ^a,d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Antipsychotic; Combination; Correlates; Polypharmacy; Rationale; Reasons; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AGE; ANXIETY; BEHAVIOR DISORDER; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE DURATION; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; ETHNICITY; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYNDROME; HUMAN; MONOTHERAPY; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SLEEP DISORDER; THERAPY RESISTANCE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS;

EID: 84865408349     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2012.06.007     Document Type: Review

References (139)

1. Kane J.M., Correll C.U. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010, 71(9):1115-1124.
2. Correll C.U. What are we looking for in new antipsychotics?. J Clin Psychiatry 2011, 72(Suppl 1):9-13.
3. Gallego J.A., Bonetti J., Zhang J.P., et al. Prevalence and correlates of antipsychotic polypharmacy from the 1970s to 2009: a systematic review and metaregression. Schizophr Res 2012, 138(1):18-28.
4. Correll C.U. Antipsychotic polypharmacy, part 1: shotgun approach or targeted cotreatment?. J Clin Psychiatry 2008, 69(4):674-675.
5. Biancosino B., Barbui C., Marmai L., et al. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 2005, 20(6):305-309.
6. Sernyak M.J., Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 2004, 65(12):1597-1600.
7. Tapp A., Wood A.E., Secrest L., et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003, 54(1):55-59.
8. Pandurangi A.K., Dalkilic A. Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 2008, 14(6):345-367.
9. McCue R.E., Waheed R., Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003, 64(9):984-989.
10. Correll C.U., Shaikh L., Gallego J.A., et al. Antipsychotic polypharmacy: prescriber attitudes, knowledge and behavior. Schizophr Res 2011, 131(1-3):58-62.
11. Stahl S.M. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret?. J Clin Psychiatry 1999, 60:425-426.
12. Stahl S.M. Antipsychotic polypharmacy: evidence based or eminence based?. Acta Psychiatr Scand 2002, 106(5):321-322.
13. Stahl S.M. Antipsychotic polypharmacy: squandering precious resources?. J Clin Psychiatry 2002, 63(2):93-94.
14. Stahl S.M., Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004, 11(3):313-327.
15. Meltzer H.Y., Kostakoglu A.E. Combining antipsychotics: is there evidence for efficacy?. Psychiatr Times 2000, 17:25-34.
16. Weiden P.J., Casey D.E. "Polypharmacy": combining antipsychotic medications in the treatment of schizophrenia. J Psychiatr Pract 1999, 5:229-233.
17. Goren J.L., Parks J.J., Ghinassi F.A., et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 2008, 34(10):571-582.
18. Correll C.U., Rummel-Kluge C., Corves C., et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009, 35(2):443-457.
19. Barbui C., Signoretti A., Mulè S., et al. Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophr Bull 2009, 35(2):458-468.
20. Rupnow M.F., Greenspan A., Gharabawi G.M., et al. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin 2007, 23(11):2815-2822.
21. Zhu B., Ascher-Svanum H., Faries D.E., et al. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 2008, 8:19.
22. Stahl S.M., Grady M.M. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv 2006, 57(1):127-129.
23. Correll C.U. From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010, 25(Suppl 2):S12-S21.
24. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Schizophrenia Patient Outcomes Research Team (PORT), et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36(1):71-93.
25. National Institute for Clinical Excellence Schizophrenia: full national guideline on core interventions in primary and secondary care 2003, The British Psychological Society and The Royal College of Psychiatrists, Leicester (UK) and London.
26. Moore T.A., Buchanan R.W., Buckley P.F., et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007, 68(11):1751-1762.
27. McGorry P.D. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005, 39(1-2):1-30.
28. Falkai P., Wobrock T., Lieberman J., et al. World Federation of Societies of Biological Psychiatry (WFSBP)-guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005, 6(3):132-191.
29. Lehman A.F., Lieberman J.A., Dixon L.B., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161(Suppl 2):1-56.
30. Nasrallah H.A., Keshavan M.S., Benes F.M., et al. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. J Clin Psychiatry 2009, 70(Suppl 1):4-46.
31. Gallego J.A., Nielsen J., DeHert M., et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety 2012, 11(4):527-542.
32. Aparasu R.R., Jano E., Bhatara V. Concomitant antipsychotic prescribing in US outpatient settings. Res Social Adm Pharm 2009, 5(3):234-241.
33. Molina J.D., Lerma-Carrillo I., Leonor M., et al. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study. Clin Neuropharmacol 2009, 32(1):10-15.
34. Lerma-Carrillo I., de Pablo Bruhlmann S., del Pozo M.L., et al. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit. Clin Neuropharmacol 2008, 31(6):319-332.
35. Morrato E.H., Dodd S., Oderda G., et al. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 2007, 29(1):183-195.
36. Kreyenbuhl J., Marcus S.C., West J.C., et al. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv 2007, 58(7):983-990.
37. Kogut S.J., Yam F., Dufresne R. Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm 2005, 11(1):17-24.
38. Jaffe A.B., Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003, 12(1):41-48.
39. Weissman E.M. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 2002, 28(1):31-42.
40. Leslie D.L., Rosenheck R.A. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 2001, 39(9):923-933.
41. Raschetti R., Spila Alegiani S., Diana G., et al. Antipsychotic drug prescription in general practice in Italy. Acta Psychiatr Scand 1993, 87(5):317-321.
42. Lass J., Mannik A., Bell J.S. Pharmacotherapy of first episode psychosis in Estonia: comparison with national and international treatment guidelines. J Clin Pharm Ther 2008, 33(2):165-173.
43. Constantine R.J., Boaz T., Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther 2010, 32(5):949-959.
44. Covell N.H., Jackson C.T., Evans A.C., et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002, 28(1):17-29.
45. Connolly A., Rogers P., Taylor D. Antipsychotic prescribing quality and ethnicity: a study of hospitalized patients in south east London. J Psychopharmacol 2007, 21(2):191-197.
46. Santone G., Bellantuono C., Rucci P., et al. Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiol Drug Saf 2011, 20(5):441-449.
47. Millier A., Sarlon E., Azorin J.M., et al. Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis. BMC Psychiatry 2011, 11:24.
48. Procyshyn R.M., Honer W.G., Wu T.K., et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010, 71(5):566-573.
49. Castberg I., Spigset O. Prescribing patterns and the use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit. Ther Drug Monit 2008, 30(5):597-603.
50. Correll C.U., Frederickson A.M., Kane J.M., et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res 2007, 89(1-3):91-100.
51. Procyshyn R.M., Thompson B. Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 2004, 37(1):12-17.
52. Lelliott P., Paton C., et al. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. The Psychiatrist 2002, 26:311-414.
53. Fourrier A., Gasquet I., Allicar M.P., et al. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000, 49(1):80-86.
54. De Hert M., Wampers M., Peuskens J. Pharmacological treatment of hospitalised schizophrenic patients in Belgium. Int J Psychiatry Clin Pract 2006, 10(4):285-290.
55. Barbui C., Nose M., Mazzi M.A., et al. Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 2006, 21(2):73-79.
56. Sim K., Su A., Fujii S., et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004, 58(2):178-183. [Erratum appears in: Br J Clin Pharmacol 2004;58(5):564].
57. Janssen B., Weinmann S., Berger M., et al. Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 2004, 30(4):1023-1033.
58. Correll CU, Kane JM, O'Shea D, et al. Antipsychotic polypharmacy in the treatment of schizophrenia. Poster presented at the International Congress on Schizophrenia Research. Colorado Springs (CO); March 29-April 2, 2003.
59. Chong M.Y., Tan C.H., Fujii S., et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004, 58(1):61-67.
60. Yip K.C., Ungvari G.S., Cheung H.K., et al. A survey of antipsychotic treatment for schizophrenia in Hong Kong. Chin Med J (Engl) 1997, 110(10):792.
61. Stroup T.S., Lieberman J.A., McEvoy J.P., et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009, 107(1):1-12.
62. Centorrino F., Fogarty K.V., Sani G., et al. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol 2005, 20(7):485-492.
63. Weinmann S., Janssen B., Gaebel W. Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. J Clin Psychiatry 2004, 65(8):1099-1105.
64. Schumacher J.E., Makela E.H., Griffin H.R. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 2003, 37(7-8):951-955.
65. Brunot A., Lachaux B., Sontag H., et al. Pharmaco-epidemiological study on antipsychotic drug prescription in French psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale 2002, 28(2):129-138.
66. Tomasi R., de Girolamo G., Santone G., et al. The prescription of psychotropic drugs in psychiatric residential facilities: a national survey in Italy. Acta Psychiatr Scand 2006, 113(3):212-223.
67. Paton C., Esop R., Young C., et al. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004, 110(4):299-305.
68. Ganguly R., Kotzan J.A., Miller L.S., et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004, 65910:1377-1388.
69. Gilmer T.P., Dolder C.R., Folsom D.P., et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007, 58(7):1007-1010.
70. Kreyenbuhl J.A., Valenstein M., McCarthy J.F., et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007, 58(4):489-495.
71. Tibaldi G., Munizza C., Bollini P., et al. Utilization of neuroleptic drugs in Italian mental health services: a survey in Piedmont. Psychiatr Serv 1997, 48(2):213-217.
72. Ghio L., Natta W., Gotelli S., et al. Antipsychotic utilisation and polypharmacy in Italian residential facilities: a survey. Epidemiol Psychiatr Sci 2011, 20(2):171-179.
73. Centorrino F., Goren J.L., Hennen J., et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004, 161(4):700-706.
74. Ahn J., McCombs J.S., Jung C., et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 2008, 11(1):48-56.
75. Simon A.E., Peter M., Hess L., et al. Antipsychotic use in patients with schizophrenia treated in private psychiatry. Swiss Med Wkly 2005, 135(7-8):109-115.
76. Barbui C., Nose M., Mazzi M.A., et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 2006, 21(6):355-362.
77. Ranceva N., Ashraf W., Odelola D. Antipsychotic polypharmacy in outpatients at Birch Hill Hospital: incidence and adherence to guidelines. J Clin Pharmacol 2010, 50(6):699-704.
78. Elie D., Poirier M., Chianetta J., et al. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol 2010, 24(7):1037-1044.
79. Centorrino F., Cincotta S.L., Talamo A., et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry 2008, 49(1):65-69.
80. Hung G.B., Cheung H.K. Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong. Hong Kong Med J 2008, 14(1):35-39.
81. Paton C., Barnes T.R., Cavanagh M.R., et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008, 192(6):435-439.
82. Wheeler A., Humberstone V., Robinson G. Trends in antipsychotic prescribing in schizophrenia in Auckland. Australas Psychiatry 2006, 14(2):169-174.
83. Humberstone V., Wheeler A., Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry 2004, 38(4):240-245.
84. Carnahan R.M., Lund B.C., Perry P.J., et al. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 2006, 113(2):135-141.
85. Florez Menendez G., Blanco Ramos M., Gomez-Reino Rodriguez I., et al. Polypharmacy in the antipsychotic prescribing in practices psychiatric out-patient clinic. Actas Esp Psiquiatr 2004, 32(6):333-339.
86. Linden M., Scheel T., Xaver Eich F. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Hum Psychopharmacol 2004, 19(2):111-119.
87. Bingefors K., Isacson D., Lindström E. Dosage patterns of antipsychotic drugs for the treatment of schizophrenia in Swedish ambulatory clinical practice-a highly individualized therapy. Nord J Psychiatry 2003, 57(4):263-269.
88. Suzuki T., Uchida H., Tanaka K.F., et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol 2003, 18(6):323-329.
89. Centorrino F., Eakin M., Bahk W.M., et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002, 159(11):1932-1935.
90. Harrington M., Lelliott P., Paton C., et al. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatr Bull 2002, 26(11):414.
91. Chong S.A., Remington G.J., Lee N., et al. Contrasting clozapine prescribing patterns in the east and west?. Ann Acad Med Singap 2000, 29(1):75-78.
92. Tognoni G. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Eur J Clin Pharmacol 1999, 55(9):685-690.
93. Galletly C.A., Tsourtos G. Antipsychotic drug doses and adjunctive drugs in the outpatient treatment of schizophrenia. Ann Clin Psychiatry 1997, 9(2):77-80.
94. Rosholm J.U., Hallas J., Gram L.F. Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients-a prescription database study. Br J Clin Pharmacol 1994, 37(6):533-538.
95. Remington G.J., Prendergast P., Bezchlibnyk-Butler K.Z. Dosaging patterns in schizophrenia with depot, oral and combined neuroleptic therapy. Can J Psychiatry 1993, 38(3):159-161.
96. Faries D., Ascher-Svanum H., Zhu B. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5:26.
97. Stahl S.M. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?. Int J Neuropsychopharmacol 2004, 7(2):113-116.
98. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999, 60(Suppl 10):20-30.
99. Hori H., Noguchi H., Hashimoto R., et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006, 86(1-3):138-146.
100. Xiang Y.T., Weng Y.Z., Leung C.M., et al. Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther 2008, 46(5):245-251.
101. Chiu H.F., Shum P.S., Lam C.W. Psychotropic drug prescribing to chronic schizophrenics in a Hong Kong hospital. Int J Soc Psychiatry 1991, 37(3):187.
102. Divac N., Jasovic-Gasic M., Samardzic R., et al. Antipsychotic polypharmacy at the University Psychiatric Hospital in Serbia. Pharmacoepidemiol Drug Saf 2007, 16(11):1250-1251.
103. Taylor M., Shajahan P., Lawrie S.M. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2008, 69(2):240-245.
104. Shajahan P., Macrae A., Bashir M., et al. Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. J Psychopharmacol 2008, 22(7):778-783.
105. Hong I.S., Bishop J.R. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother 2010, 44(7-8):1171-1180.
106. Chakos M.H., Glick I.D., Miller A.L., et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006, 57(8):1094-1101.
107. Procyshyn R.M., Kennedy N.B., Tse G., et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001, 46(4):334-339.
108. Taylor D., Mace S., Mir S., et al. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000, 4(1):41-46.
109. Brambilla P., Monzani E., Alessandri M., et al. Uso di psicofarmaci presso l'ex ospedale psichiatrico di Milano: uno studio di follow-up. Epidemiologia e Psichiatria Sociale 1999, 8:262-269. [in Italian].
110. Hida H., Faber M., Alberto-Gondouin M., et al. Analyse des prescriptions de psychotropes dans un Centre Hospitalier Psychiatrique-a survey of psychotropic drugs prescribing in a psychiatric hospital. Thèrapie 1997, 52(6):573-578. [in French].
111. Kiivet R.A., Llerena A., Dahl M.L., et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 1995, 40(5):467-476.
112. Clark A., Holden N. The persistence of prescribing habits: a survey and follow-up of prescribing to chronic hospital in-patients. Br J Psychiatry 1987, 150:88.
113. Morgan R., Gopalaswamy A.K. Psychotropic drugs: another survey of prescribing patterns. Br J Psychiatry 1984, 144:298-302.
114. Mason A.S., Nerviano V., DeBurger R.A. Patterns of antipsychotic drug use in four Southeastern state hospitals. Dis Nerv Syst 1977, 38(7):541-545.
115. Patrick V., Schleifer S.J., Nurenberg J.R., et al. Best practices: an initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 2006, 57(1):21-23.
116. Muscettola G., Casiello M., Bolline P., et al. Pattern of therapeutic intervention and role of psychiatric settings: a survey in two regions of Italy. Acta Psychiatr Scand 1987, 75(1):55-61.
117. Muijen M., Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 1987, 150:501-504.
118. Edwards S., Kumar V. A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital. Br J Psychiatry 1984, 145:502-507.
119. Baandrup L., Allerup P., Nordentoft M., et al. Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. J Clin Psychiatry 2010, 71(11):1457-1464.
120. Johnson D.A., Wright N.F. Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years. Br J Psychiatry 1990, 156:827-834.
121. Kreyenbuhl J., Valenstein M., McCarthy J.F., et al. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 2006, 84(1):90-99.
122. Baandrup L., Sørensen J., Lublin H., et al. Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. Eur J Health Econ 2012, 13(3):355-363.
123. Valuck R.J., Morrato E.H., Dodd S., et al. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs. Curr Med Res Opin 2007, 23(10):2567-2576.
124. Loosbrock D.L., Zhao Z., Johnstone B.M., et al. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ 2003, 6(2):67-75.
125. Clark R.E., Bartels S.J., Mellman T.A., et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002, 28(1):75-84.
126. Kumra S., Kranzler H., Gerbino-Rosen G., et al. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol 2008, 18(4):307-316.
127. Nielsen J., Dahm M., Lublin H., et al. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010, 24(7):965-971.
128. Correll C.U. Real-life dosing with second-generation antipsychotics. J Clin Psychiatry 2005, 66(12):1610-1611.
129. Robinson D., Woerner M.G., Pollack S., et al. Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol 1996, 16(2):170-176.
130. Hofer A., Hummer M., Huber R., et al. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 2000, 20(6):699-702.
131. Correll C.U., Kishimoto T., Nielsen J., et al. Clinical relevance of treatments for schizophrenia. Clin Ther 2011, 33(12):B16-B39.
132. Correll C.U., Kishimoto T., Kane J.M. Randomized controlled trials in schizophrenia: opportunities, limitations and novel trial designs. Dialogues Clin Neurosci 2011, 13(2):155-172.
133. Kinon B.J., Kane J.M., Johns C., et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993, 29(2):309-314.
134. Baune B.T. New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. Neuropsychiatr Dis Treat 2008, 4(6):1181-1191.
135. Hazra M., Uchida H., Sproule B., et al. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry Clin Neurosci 2011, 65(7):676-678.
136. Suzuki T., Uchida H., Tanaka K.F., et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 2004, 7(2):133-142.
137. Essock S.M., Schooler N.R., Stroup T.S., et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011, 168(7):702-708.
138. Essali A., Al-Haj Haasan N., Li C., et al. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009, (1). CD000059.
139. Leucht S., Komossa K., Rummel-Kluge C., et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009, 166(2):152-163.